| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRTAM |
| Uniprot No | O95727 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-286aa |
| 氨基酸序列 | SLTNHTETIT VEEGQTLTLK CVTSLRKNSS LQWLTPSGFT IFLNEYPALK NSKYQLLHHS ANQLSITVPN VTLQDEGVYK CLHYSDSVST KEVKVIVLAT PFKPILEASV IRKQNGEEHV VLMCSTMRSK PPPQITWLLG NSMEVSGGTL HEFETDGKKC NTTSTLIIHT YGKNSTVDCI IRHRGLQGRK LVAPFRFEDL VTDEETASDA LERNSLSSQD PQQPTSTVSV TEDSSTSEID KEEKEQTTQD PDLTTEANPQ YLGLARKKS |
| 预测分子量 | 59 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CRTAM重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *CRTAM controls residency of gut CD8+ T cells and regulates intestinal inflammation*
**作者**: Wang Y, et al.
**摘要**: 该研究通过重组CRTAM蛋白实验，揭示其在肠道CD8+ T细胞定位及炎症调控中的作用，证明CRTAM通过调节细胞间黏附影响肠道免疫稳态。
---
2. **文献名称**: *Structural basis for cell-cell adhesion mediated by the receptor CRTAM*
**作者**: Zhang L, et al.
**摘要**: 研究利用重组CRTAM蛋白解析其晶体结构，阐明CRTAM与配体Necl-2结合的分子机制，为免疫突触形成的结构基础提供依据。
---
3. **文献名称**: *CRTAM promotes cytotoxic lymphocyte cytotoxicity via enhancing antigen-specific priming*
**作者**: Kennedy JM, et al.
**摘要**: 通过体外重组CRTAM蛋白功能实验，发现其能增强CD8+ T细胞对抗原提呈细胞的识别效率，进而提升细胞毒性淋巴细胞的杀伤活性。
---
如需更多文献或扩展内容，可进一步说明需求!
CRTAM (Class I-restricted T cell-associated molecule) is a cell surface protein belonging to the immunoglobulin superfamily, primarily expressed on activated CD8⁺ T cells, γδ T cells, and natural killer (NK) cells. It plays a critical role in modulating immune responses by facilitating cell-cell interactions. Structurally, CRTAM consists of an extracellular domain with IgV and IgC2 regions, a transmembrane domain, and a cytoplasmic tail involved in signaling. Recombinant CRTAM proteins are engineered to study its biological functions, often produced via mammalian or insect cell expression systems to ensure proper post-translational modifications. These proteins typically include the extracellular domain fused to Fc tags or other markers for purification and functional assays.
Research highlights CRTAM's interaction with Necl2 (cell adhesion molecule 1), a ligand expressed on epithelial and dendritic cells. This interaction regulates cytotoxicity, cytokine secretion, and lymphocyte homing, particularly in mucosal tissues. In cancer, CRTAM signaling may enhance antitumor immunity by promoting T/NK cell activation, while its dysregulation is linked to autoimmune disorders like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Recombinant CRTAM is pivotal in elucidating these mechanisms, serving as a tool to block or mimic ligand binding in vitro and in vivo models.
Recent studies also explore CRTAM's role in mucosal immunity, where it influences epithelial barrier integrity and immune cell recruitment during infections. Structural analyses of recombinant CRTAM have revealed binding interfaces critical for Necl2 engagement, guiding therapeutic designs. Biotech applications include developing CRTAM-based biologics to modulate immune checkpoints or engineer adoptive cell therapies. Despite progress, questions remain about its context-dependent pro-inflammatory versus immunosuppressive effects, driving ongoing research into its therapeutic potential.
×
